Xuechu Zhen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1176874/publications.pdf

Version: 2024-02-01

148 papers

5,610 citations

43 h-index 106344 65 g-index

149 all docs

149 docs citations

149 times ranked 7656 citing authors

#	Article	IF	CITATIONS
1	Discovery of novel MIF inhibitors that attenuate microglial inflammatory activation by structures-based virtual screening and in vitro bioassays. Acta Pharmacologica Sinica, 2022, 43, 1508-1520.	6.1	10
2	Dysregulation of iron homeostasis and methamphetamine reward behaviors in Clk1-deficient mice. Acta Pharmacologica Sinica, 2022, 43, 1686-1698.	6.1	6
3	Dopamine D1 receptors mediate methamphetamine-induced dopaminergic damage: involvement of autophagy regulation via the AMPK/FOXO3A pathway. Psychopharmacology, 2022, 239, 951-964.	3.1	4
4	Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects. Schizophrenia Bulletin, 2022, 48, 474-484.	4.3	6
5	Sigma-1 receptor regulates mitophagy in dopaminergic neurons and contributes to dopaminergic protection. Neuropharmacology, 2021, 196, 108360.	4.1	12
6	Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach. Journal of Neuroscience Research, 2021, 99, 1308-1324.	2.9	16
7	Early glycolytic reprogramming controls microglial inflammatory activation. Journal of Neuroinflammation, 2021, 18, 129.	7.2	73
8	Inhibition of neuroinflammation by MIF inhibitor 3-($\{[4-(4-methoxyphenyl)-6-methyl-2-pyrimidinyl]thio\}1methyl)benzoic acid (Z-312). International Immunopharmacology, 2021, 98, 107868.$	3.8	5
9	Absence of TRIM32 Leads to Reduced GABAergic Interneuron Generation and Autism-like Behaviors in Mice via Suppressing mTOR Signaling. Cerebral Cortex, 2020, 30, 3240-3258.	2.9	24
10	Protective Effect of Metformin against Hydrogen Peroxide-Induced Oxidative Damage in Human Retinal Pigment Epithelial (RPE) Cells by Enhancing Autophagy through Activation of AMPK Pathway. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-14.	4.0	32
11	FoxO3a suppresses neuropeptide W expression in neuronal cells and in rat hypothalamus and its implication in hypothalamic-pituitary-adrenal (HPA) axis. International Journal of Biological Sciences, 2020, 16, 2775-2787.	6.4	3
12	Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases. Journal of Medicinal Chemistry, 2020, 63, 15187-15217.	6.4	49
13	Emerging novel approaches to drug research and diagnosis of Parkinson's disease. Acta Pharmacologica Sinica, 2020, 41, 439-441.	6.1	8
14	C9orf72 associates with inactive Rag GTPases and regulates mTORC1â€mediated autophagosomal and lysosomal biogenesis. Aging Cell, 2020, 19, e13126.	6.7	34
15	Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin. Acta Pharmacologica Sinica, 2020, 41, 499-507.	6.1	25
16	PHLDA1 promotes microglia-mediated neuroinflammation via regulating K63-linked ubiquitination of TRAF6. Brain, Behavior, and Immunity, 2020, 88, 640-653.	4.1	28
17	Knockdown of milkâ€fat globule EGF factorâ€8 suppresses glioma progression in GL261 glioma cells by repressing microglial M2 polarization. Journal of Cellular Physiology, 2020, 235, 8679-8690.	4.1	15
18	D2 receptor-mediated miRNA-143 expression is associated with the effects of antipsychotic drugs on phencyclidine-induced schizophrenia-related locomotor hyperactivity and with Neuregulin-1 expression in mice. Neuropharmacology, 2019, 157, 107675.	4.1	15

#	Article	IF	Citations
19	The oncometabolite 2-hydroxyglutarate inhibits microglial activation via the AMPK/mTOR/NF-κB pathway. Acta Pharmacologica Sinica, 2019, 40, 1292-1302.	6.1	46
20	Development of Adenosine A _{2A} Receptor Antagonists for the Treatment of Parkinson's Disease: A Recent Update and Challenge. ACS Chemical Neuroscience, 2019, 10, 783-791.	3 . 5	44
21	Developmental Genes and Regulatory Proteins, Domains of Cognitive Impairment in Schizophrenia Spectrum Psychosis and Implications for Antipsychotic Drug Discovery: The Example of Dysbindin-1 Isoforms and Beyond. Frontiers in Pharmacology, 2019, 10, 1638.	3.5	13
22	Macrophage migration inhibitory factor (MIF) inhibitor, Z-590 suppresses cartilage destruction in adjuvant-induced arthritis via inhibition of macrophage inflammatory activation. Immunopharmacology and Immunotoxicology, 2018, 40, 149-157.	2.4	13
23	miRNA-3473b contributes to neuroinflammation following cerebral ischemia. Cell Death and Disease, 2018, 9, 11.	6.3	83
24	Dysregulation of mi <scp>RNA</scp> and its potential therapeutic application in schizophrenia. CNS Neuroscience and Therapeutics, 2018, 24, 586-597.	3.9	54
25	Dihydromyricetin exerts a rapid antidepressant-like effect in association with enhancement of BDNF expression and inhibition of neuroinflammation. Psychopharmacology, 2018, 235, 233-244.	3.1	52
26	Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases. Frontiers in Cellular Neuroscience, 2018, 12, 314.	3.7	53
27	Emerging and evolving concepts in the pathobiology and treatment of psychosis. CNS Neuroscience and Therapeutics, 2018, 24, 583-585.	3.9	2
28	Morphine-induced inhibition of Ca ²⁺ -dependent <scp>d</scp> -serine release from astrocytes suppresses excitability of GABAergic neurons in the nucleus accumbens. Addiction Biology, 2017, 22, 1289-1303.	2.6	16
29	The Role of BK Channel in Microglia Activation. Biophysical Journal, 2017, 112, 548a.	0.5	1
30	Design and optimization of purine derivatives as in vivo active PDE10A inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 3315-3329.	3.0	7
31	Discovery of Novel and Selective Adenosine A _{2A} Receptor Antagonists for Treating Parkinson's Disease through Comparative Structure-Based Virtual Screening. Journal of Chemical Information and Modeling, 2017, 57, 1474-1487.	5.4	45
32	Clk1â€regulated aerobic glycolysis is involved in glioma chemoresistance. Journal of Neurochemistry, 2017, 142, 574-588.	3.9	37
33	Prediction of chemical biodegradability using computational methods. Molecular Simulation, 2017, 43, 1277-1290.	2.0	10
34	Dihydromyricetin protects against cerebral ischemia/reperfusion injury via suppressing microglia-mediated neuroinflammation and activation of ERK1/2-CREB signaling pathway. Journal of Functional Foods, 2017, 33, 76-84.	3.4	15
35	<scp>GSK</scp> â€3 <i>\hat{I}^2</i> Interacts with Dopamine D1 Receptor to Regulate Receptor Function: Implication for Prefrontal Cortical D1 Receptor Dysfunction in Schizophrenia. CNS Neuroscience and Therapeutics, 2017, 23, 174-187.	3.9	20
36	Activation of AMPK/mTORC1-Mediated Autophagy by Metformin Reverses Clk1 Deficiency-Sensitized Dopaminergic Neuronal Death. Molecular Pharmacology, 2017, 92, 640-652.	2.3	56

3

#	Article	IF	Citations
37	Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. British Journal of Pharmacology, 2017, 174, 3173-3190.	5.4	17
38	Clk1 deficiency promotes neuroinflammation and subsequent dopaminergic cell death through regulation of microglial metabolic reprogramming. Brain, Behavior, and Immunity, 2017, 60, 206-219.	4.1	42
39	Activation of Nur77 in microglia attenuates proinflammatory mediators production and protects dopaminergic neurons from inflammationâ€induced cell death. Journal of Neurochemistry, 2017, 140, 589-604.	3.9	32
40	Functional reversal of (â^')â€Stepholidine analogues by replacement of benzazepine substructure using the ringâ€expansion strategy. Chemical Biology and Drug Design, 2016, 88, 599-607.	3.2	5
41	Allosteric Modulation of Sigmaâ€1 Receptors Elicits Rapid Antidepressant Activity. CNS Neuroscience and Therapeutics, 2016, 22, 368-377.	3.9	37
42	Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity. Acta Pharmacologica Sinica, 2016, 37, 1315-1324.	6.1	77
43	GSKâ€3β inhibitors reverse cocaineâ€induced synaptic transmission dysfunction in the nucleus accumbens. Synapse, 2016, 70, 461-470.	1.2	13
44	Identification of a New Series of Potent Adenosine A _{2A} Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson's Disease. ACS Chemical Neuroscience, 2016, 7, 1575-1584.	3.5	15
45	Inhibition of macrophage migration inhibitory factor (<scp>MIF</scp>) tautomerase activity suppresses microgliaâ€mediated inflammatory responses. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 1134-1144.	1.9	39
46	Phosphodiesterase 10A inhibition attenuates sleep deprivation-induced deficits in long-term fear memory. Neuroscience Letters, 2016, 635, 44-50.	2.1	10
47	LLDT-8 protects against cerebral ischemia/reperfusion injury by suppressing post-stroke inflammation. Journal of Pharmacological Sciences, 2016, 131, 131-137.	2.5	34
48	Accessible Method for the Development of Novel Sterol Analogues with Dipeptide-like Side Chains That Act as Neuroinflammation Inhibitors. ACS Chemical Neuroscience, 2016, 7, 305-315.	3.5	5
49	Inhibition of Neuroinflammation by Synthetic Androstene Derivatives Incorporating Amino Acid Methyl Esters on Activated BVâ€2 Microglia. ChemMedChem, 2015, 10, 610-616.	3.2	8
50	Allosteric modulation of sigmaâ€1 receptors elicits antiâ€seizure activities. British Journal of Pharmacology, 2015, 172, 4052-4065.	5.4	33
51	Allosteric modulation of sigmaâ€1 receptors by <scp>SKF</scp> 83959 inhibits microgliaâ€mediated inflammation. Journal of Neurochemistry, 2015, 134, 904-914.	3.9	56
52	Neuropharmacological Actions of Metformin in Stroke. Current Neuropharmacology, 2015, 13, 389-394.	2.9	40
53	Higher-Affinity Agonists of 5-HT _{1A} R Discovered through Tuning the Binding-Site Flexibility. Journal of Chemical Information and Modeling, 2015, 55, 1616-1627.	5 . 4	11
54	Mice heterozygous for cathepsin D deficiency exhibit mania-related behavior and stress-induced depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 63, 110-118.	4.8	20

#	Article	lF	CITATIONS
55	Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3970-3974.	2.2	13
56	Anti-inflammatory effects of glaucocalyxin B in microglia cells. Journal of Pharmacological Sciences, 2015, 128, 35-46.	2.5	52
57	Discovery of 4-benzoylpiperidine and 3-(piperidin-4-yl)benzo[d]isoxazole derivatives as potential and selective GlyT1 inhibitors. RSC Advances, 2015, 5, 40964-40977.	3.6	4
58	Prefrontal cortex gates acute morphine action on dopamine neurons in the ventral tegmental area. Neuropharmacology, 2015, 95, 299-308.	4.1	17
59	MicroRNA let-7c-5p protects against cerebral ischemia injury via mechanisms involving the inhibition of microglia activation. Brain, Behavior, and Immunity, 2015, 49, 75-85.	4.1	142
60	Glial Pathology in Bipolar Disorder: Potential Therapeutic Implications. CNS Neuroscience and Therapeutics, 2015, 21, 393-397.	3.9	31
61	Design, synthesis and evaluation of a series of non-steroidal anti-inflammatory drug conjugates as novel neuroinflammatory inhibitors. International Immunopharmacology, 2015, 25, 528-537.	3.8	26
62	Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia. Cell Death and Disease, 2015, 6, e1702-e1702.	6.3	87
63	Structure–Activity Relationships and Anti-inflammatory Activities of <i>N</i> -Carbamothioylformamide Analogues as MIF Tautomerase Inhibitors. Journal of Chemical Information and Modeling, 2015, 55, 1994-2004.	5.4	6
64	Protease Omi facilitates neurite outgrowth in mouse neuroblastoma N2a cells by cleaving transcription factor E2F1. Acta Pharmacologica Sinica, 2015, 36, 966-975.	6.1	18
65	Absorption, Distribution, Metabolism, Excretion, and Toxicity Evaluation in Drug Discovery. 14. Prediction of Human Pregnane X Receptor Activators by Using Naive Bayesian Classification Technique. Chemical Research in Toxicology, 2015, 28, 116-125.	3.3	29
66	Rotenone impairs autophagic flux and lysosomal functions in Parkinson's disease. Neuroscience, 2015, 284, 900-911.	2.3	90
67	Sigma-2 Receptor Ligands: Neurobiological Effects. Current Medicinal Chemistry, 2015, 22, 989-1003.	2.4	58
68	Inhibition of phosphodiesterase 10A attenuates morphine-induced conditioned place preference. Molecular Brain, 2014, 7, 70.	2.6	22
69	Effects of SKF83959 on the excitability of hippocampal CA1 pyramidal neurons: a modeling study. Acta Pharmacologica Sinica, 2014, 35, 738-751.	6.1	4
70	Mutation of SLC35D3 Causes Metabolic Syndrome by Impairing Dopamine Signaling in Striatal D1 Neurons. PLoS Genetics, 2014, 10, e1004124.	3.5	33
71	Robo3.1A suppresses Slit-mediated repulsion by triggering degradation of Robo2. Journal of Neuroscience Research, 2014, 92, 835-846.	2.9	8
72	CaMKKÎ ² -Dependent Activation of AMP-Activated Protein Kinase Is Critical to Suppressive Effects of Hydrogen Sulfide on Neuroinflammation. Antioxidants and Redox Signaling, 2014, 21, 1741-1758.	5.4	116

#	Article	IF	Citations
73	Naja naja atra venom ameliorates pulmonary fibrosis by inhibiting inflammatory response and oxidative stress. BMC Complementary and Alternative Medicine, 2014, 14, 461.	3.7	15
74	Topsendines A–F, new 3-alkylpyridine alkaloids from a Hainan sponge Topsentia sp Tetrahedron, 2014, 70, 3166-3171.	1.9	10
75	Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 152-155.	2.2	13
76	Structural manipulation on the catecholic fragment of dopamine D1 receptor agonist 1-phenyl-N-methyl-benzazepines. European Journal of Medicinal Chemistry, 2014, 85, 16-26.	5.5	11
77	Discovery of Novel Inhibitors Targeting the Macrophage Migration Inhibitory Factor via Structure-Based Virtual Screening and Bioassays. Journal of Medicinal Chemistry, 2014, 57, 3737-3745.	6.4	66
78	Assessing an Ensemble Docking-Based Virtual Screening Strategy for Kinase Targets by Considering Protein Flexibility. Journal of Chemical Information and Modeling, 2014, 54, 2664-2679.	5.4	96
79	(6aR)-11-Amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease. Pharmacology Biochemistry and Behavior, 2014, 124, 204-210.	2.9	24
80	Optimization of 6-Heterocyclic-2-(1 <i>H</i> -pyrazol-1-yl)- <i>N</i> -(pyridin-2-yl)pyrimidin-4-amine as Potent Adenosine A _{2A} Receptor Antagonists for the Treatment of Parkinson's Disease. ACS Chemical Neuroscience, 2014, 5, 674-682.	3.5	20
81	Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles. Bioorganic and Medicinal Chemistry, 2014, 22, 5838-5846.	3.0	9
82	Synthesis of $5\hat{l}$ ±-cholestan-6-one derivatives and their inhibitory activities of NO production in activated microglia: Discovery of a novel neuroinflammation inhibitor. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1222-1227.	2.2	20
83	Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. Brain, Behavior, and Immunity, 2014, 40, 131-142.	4.1	234
84	1-O-Tigloyl-1-O-deacetyl-nimbolinin B Inhibits LPS-Stimulated Inflammatory Responses by Suppressing NF-ÎB and JNK Activation in Microglia Cells. Journal of Pharmacological Sciences, 2014, 125, 364-374.	2.5	37
85	Antiinflammatory Effects of Orientin-2″- <i>O</i> Galactopyranoside on Lipopolysaccharide-Stimulated Microglia. Biological and Pharmaceutical Bulletin, 2014, 37, 1282-1294.	1.4	33
86	A Computational Perspective on Drug Discovery and Signal Transduction Mechanism of Dopamine and Serotonin Receptors in the Treatment of Schizophrenia. Current Pharmaceutical Biotechnology, 2014, 15, 916-926.	1.6	5
87	Differential mechanisms underlying neuroprotection of hydrogen sulfide donors against oxidative stress. Neurochemistry International, 2013, 62, 1072-1078.	3.8	60
88	Molecular Modeling of the 3D Structure of 5-HT1AR: Discovery of Novel 5-HT1AR Agonists via Dynamic Pharmacophore-Based Virtual Screening. Journal of Chemical Information and Modeling, 2013, 53, 3202-3211.	5.4	26
89	Delayed administration of a PTEN inhibitor BPV improves functional recovery after experimental stroke. Neuroscience, 2013, 231, 272-281.	2.3	76
90	Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D1, D2 and serotonin 5-HT1A multi-action profile. Bioorganic and Medicinal Chemistry, 2013, 21, 856-868.	3.0	64

#	Article	IF	CITATIONS
91	Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders. Chemical Reviews, 2013, 113, PR123-PR178.	47.7	77
92	Current developments of macrophage migration inhibitory factor (MIF) inhibitors. Drug Discovery Today, 2013, 18, 592-600.	6.4	81
93	SKF83959 is a novel triple reuptake inhibitor that elicits anti-depressant activity. Acta Pharmacologica Sinica, 2013, 34, 1149-1155.	6.1	17
94	CMYA5: a new potential substrate of Kcna3 in human heart. Acta Biochimica Et Biophysica Sinica, 2013, 45, 236-238.	2.0	2
95	SKF83959 Is a Potent Allosteric Modulator of Sigma-1 Receptor. Molecular Pharmacology, 2013, 83, 577-586.	2.3	47
96	Design, Synthesis, and Evaluation of Indolebutylamines as a Novel Class of Selective Dopamine <scp>D</scp> 3 Receptor Ligands. Chemical Biology and Drug Design, 2013, 82, 326-335.	3.2	4
97	Postischemic Administration of a Potent <scp>PTEN</scp> Inhibitor Reduces Spontaneous Lung Infection Following Experimental Stroke. CNS Neuroscience and Therapeutics, 2013, 19, 990-993.	3.9	2
98	Synthesis, preliminary pharmacological evaluation and receptor docking studies of 10-amino-3-methoxy-6,8,12,12a-tetrahydro-5H-thiazolo[4',5':4,5]pyrido[2,1-a]isoquinolin-2-ols as novel dopamine D1 receptor inhibitors. Vedic Research International Biological Medicinal Chemistry, 2013, 1, 38.	0.0	0
99	Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: Selective inhibitors of dopamine D1 receptor. Bioorganic and Medicinal Chemistry, 2012, 20, 4862-4871.	3.0	27
100	L166P mutant DJ-1 promotes cell death by dissociating Bax from mitochondrial Bcl-XL. Molecular Neurodegeneration, 2012, 7, 40.	10.8	32
101	Generation and characterization of hD5 and C-terminal Mutant hD5m transgenic rats. Brain Research, 2012, 1448, 27-41.	2.2	1
102	GABA Neurons in the Ventral Tegmental Area Responding to Peripheral Sensory Input. PLoS ONE, 2012, 7, e51507.	2.5	11
103	Methylphenidate Enhances NMDA-Receptor Response in Medial Prefrontal Cortex via Sigma-1 Receptor: A Novel Mechanism for Methylphenidate Action. PLoS ONE, 2012, 7, e51910.	2.5	28
104	Identification of $\langle i \rangle N \langle i \rangle$ -Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson's Agent Possessing a Dopamine D $\langle sub \rangle 2 \langle sub \rangle$ and Serotonin 5-HT $\langle sub \rangle 1A \langle sub \rangle$ Dual-Agonist Profile. Journal of Medicinal Chemistry, 2011, 54, 4324-4338.	6.4	40
105	Further SAR study on 11-O-substituted aporphine analogues: Identification of highly potent dopamine D3 receptor ligands. Bioorganic and Medicinal Chemistry, 2011, 19, 1999-2008.	3.0	17
106	SKF83959 suppresses excitatory synaptic transmission in rat hippocampus via a dopamine receptorâ€independent mechanism. Journal of Neuroscience Research, 2011, 89, 1259-1266.	2.9	16
107	The Retardation of Myometrial Infiltration, Reduction of Uterine Contractility, and Alleviation of Generalized Hyperalgesia in Mice With Induced Adenomyosis by Levo-Tetrahydropalmatine (I-THP) and Andrographolide. Reproductive Sciences, 2011, 18, 1025-1037.	2.5	53
108	Levo-Tetrahydropalmatine Retards the Growth of Ectopic Endometrial Implants and Alleviates Generalized Hyperalgesia in Experimentally Induced Endometriosis in Rats. Reproductive Sciences, 2011, 18, 28-45.	2.5	41

#	Article	IF	Citations
109	Activation of phosphatidylinositol-linked D1-like receptors increases spontaneous glutamate release in rat somatosensory cortical neurons in vitro. Brain Research, 2010, 1343, 20-27.	2.2	20
110	Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels in the regulation of midbrain dopamine systems. Acta Pharmacologica Sinica, 2010, 31, 1036-1043.	6.1	41
111	Synthesis of Dihydrofuroaporphine Derivatives: Identification of a Potent and Selective Serotonin 5-HT _{1A} Receptor Agonist. Journal of Medicinal Chemistry, 2010, 53, 1319-1328.	6.4	37
112	l-Stepholidine reduced l-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neurobiology of Aging, 2010, 31, 926-936.	3.1	39
113	Tetrahydroberberine blocks ATP-sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra pars compacta. Neuropharmacology, 2010, 59, 567-572.	4.1	29
114	Electrophysiological Effects of SKF83959 on Hippocampal CA1 Pyramidal Neurons: Potential Mechanisms for the Drug's Neuroprotective Effects. PLoS ONE, 2010, 5, e13118.	2.5	12
115	Activation of Phosphatidylinositol-Linked D1-Like Receptor Modulates FGF-2 Expression in Astrocytes via IP3-Dependent Ca2+ Signaling. Journal of Neuroscience, 2009, 29, 7766-7775.	3.6	52
116	Dopamine D ₁ receptor ligands: Where are we now and where are we going. Medicinal Research Reviews, 2009, 29, 272-294.	10.5	117
117	â€~Click' D1 receptor agonists with a 5-HT1A receptor pharmacophore producing D2 receptor activity. Bioorganic and Medicinal Chemistry, 2009, 17, 4873-4880.	3.0	37
118	Distinctive nicotinic acetylcholine receptor functional phenotypes of rat ventral tegmental area dopaminergic neurons. Journal of Physiology, 2009, 587, 345-361.	2.9	69
119	PSD-95 regulates D1 dopamine receptor resensitization, but not receptor-mediated Gs-protein activation. Cell Research, 2009, 19, 612-624.	12.0	25
120	Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand. Schizophrenia Research, 2009, 115, 41-49.	2.0	27
121	Arylbenzazepines Are Potent Modulators for the Delayed Rectifier K+ Channel: A Potential Mechanism for Their Neuroprotective Effects. PLoS ONE, 2009, 4, e5811.	2.5	11
122	Recent Development in Studies of Tetrahydroprotoberberines: Mechanism in Antinociception and Drug Addiction. Cellular and Molecular Neurobiology, 2008, 28, 491-499.	3.3	129
123	Estrogen regulates responses of dopamine neurons in the ventral tegmental area to cocaine. Psychopharmacology, 2008, 199, 625-635.	3.1	82
124	Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorganic and Medicinal Chemistry, 2008, 16, 6675-6681.	3.0	23
125	N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D2 and serotonin 5-HT1A receptor dual ligands. Bioorganic and Medicinal Chemistry, 2008, 16, 8335-8338.	3.0	12
126	Synthesis of 6-substituted 1-phenylbenzazepines and their dopamine D1 receptor activities. Bioorganic and Medicinal Chemistry, 2008, 16, 9425-9431.	3.0	12

#	Article	IF	CITATIONS
127	Neuroprotective effects of atypical D ₁ receptor agonist SKF83959 are mediated via D ₁ receptorâ€dependent inhibition of glycogen synthase kinaseâ€3β and a receptorâ€independent antiâ€oxidative action. Journal of Neurochemistry, 2008, 104, 946-956.	3.9	53
128	Single Dose of Morphine Produced a Prolonged Effect on Dopamine Neuron Activities. Molecular Pain, 2008, 4, 1744-8069-4-57.	2.1	31
129	Recent Developments in Studies of l-Stepholidine and its Analogs: Chemistry, Pharmacology and Clinical Implications. Current Medicinal Chemistry, 2007, 14, 2996-3002.	2.4	53
130	Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neuropharmacology, 2007, 53, 125-133.	4.1	44
131	Estrogen-modulated frontal cortical CaMKII activity and behavioral supersensitization induced by prolonged cocaine treatment in female rats. Psychopharmacology, 2007, 191, 323-331.	3.1	13
132	Modulation of Ca2+ signals by phosphatidylinositol-linked novel D1 dopamine receptor in hippocampal neurons. Journal of Neurochemistry, 2006, 98, 1316-1323.	3.9	58
133	The role of the phosphatidyinositol-linked D dopamine receptor in the pharmacology of SKF83959. Pharmacology Biochemistry and Behavior, 2005, 80, 597-601.	2.9	45
134	Regulation of Cyclin-Dependent Kinase 5 and Calcium/Calmodulin-Dependent Protein Kinase II by Phosphatidylinositol-Linked Dopamine Receptor in Rat Brain. Molecular Pharmacology, 2004, 66, 1500-1507.	2.3	32
135	SKF83959 selectively regulates phosphatidylinositolâ€inked D ₁ dopamine receptors in rat brain. Journal of Neurochemistry, 2003, 85, 378-386.	3.9	129
136	Prenatal cocaine exposure alters glycogen synthase kinase-3Î ² (GSK3Î ²) pathway in select rabbit brain areas. Neuroscience Letters, 2003, 349, 143-146.	2.1	16
137	Inhibition of Protein Tyrosine/Mitogen-Activated Protein Kinase Phosphatase Activity Is Associated with D2 Dopamine Receptor Supersensitivity in a Rat Model of Parkinson's Disease. Molecular Pharmacology, 2002, 62, 1356-1363.	2.3	35
138	Lithium regulates protein tyrosine phosphatase activity in vitro and in vivo. Psychopharmacology, 2002, 162, 379-384.	3.1	11
139	The p38 Mitogen-Activated Protein Kinase Is Involved in Associative Learning in Rabbits. Journal of Neuroscience, 2001, 21, 5513-5519.	3.6	54
140	Prenatal Exposure to Cocaine Disrupts D _{1A} Dopamine Receptor Function Via Selective Inhibition of Protein Phosphatase 1 Pathway in Rabbit Frontal Cortex. Journal of Neuroscience, 2001, 21, 9160-9167.	3.6	65
141	Mitogen-activated Protein Kinase p38 Mediates Regulation of Chondrocyte Differentiation by Parathyroid Hormone. Journal of Biological Chemistry, 2001, 276, 4879-4885.	3.4	88
142	Osteopontin Gene Regulation by Oscillatory Fluid Flow via Intracellular Calcium Mobilization and Activation of Mitogen-activated Protein Kinase in MC3T3–E1 Osteoblasts. Journal of Biological Chemistry, 2001, 276, 13365-13371.	3.4	342
143	Activation of Extracellular Signal-Regulated Protein Kinases Is Associated with a Sensitized Locomotor Response to D ₂ Dopamine Receptor Stimulation in Unilateral 6-Hydroxydopamine-Lesioned Rats. Journal of Neuroscience, 2000, 20, 1849-1857.	3.6	74
144	Age-Associated Impairment in Brain MAPK Signal Pathways and the Effect of Caloric Restriction in Fischer 344 Rats. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 1999, 54, B539-B548.	3.6	72

Xuechu Zhen

#	Article	IF	CITATION
145	D ₁ Dopamine Receptor Agonists Mediate Activation of p38 Mitogen-Activated Protein Kinase and c-Jun Amino-Terminal Kinase by a Protein Kinase A-Dependent Mechanism in SK-N-MC Human Neuroblastoma Cells. Molecular Pharmacology, 1998, 54, 453-458.	2.3	73
146	Platelet-Derived Growth Factor Stimulates Sodium-Dependent Pi Transport in Osteoblastic Cells via Phospholipase \hat{Cl}^3 and Phosphatidylinositol $3\hat{a}\in^2$ -Kinase. Journal of Bone and Mineral Research, 1997, 12, 36-44.	2.8	43
147	PSD-95 Interacts with Dopamine D1-Receptor: Functional Implication. American Journal of Biomedical Sciences, 0, , 313-321.	0.2	1
148	Development and Evaluation of Novel Metformin Derivative Metformin Threonate for Brain Ischemia Treatment. Frontiers in Pharmacology, $0,13,.$	3.5	7